亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

医学 Evolocumab公司 中期分析 以兹提米比 内科学 不利影响 PCSK9 低密度脂蛋白单采 家族性高胆固醇血症 胆固醇 临床试验 脂蛋白 低密度脂蛋白受体 载脂蛋白A1
作者
Frederick J. Raal,G. Kees Hovingh,Dirk Blom,Raúl D. Santos,Mariko Harada‐Shiba,Éric Bruckert,Patrick Couture,Handrean Soran,Gerald F. Watts,Christopher E. Kurtz,Narimon Honarpour,Lihua Tang,Sree Kasichayanula,Scott M. Wasserman,Evan A. Stein
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier]
卷期号:5 (4): 280-290 被引量:202
标识
DOI:10.1016/s2213-8587(17)30044-x
摘要

Background Homozygous familial hypercholesterolaemia is a genetic disorder characterised by substantially raised LDL cholesterol, reduced LDL receptor function, xanthomas, and cardiovascular disease before age 20 years. Conventional therapy is with statins, ezetimibe, and apheresis. We aimed to assess the long-term safety and efficacy of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab in a subset of patients with homozygous familial hypercholesterolaemia enrolled in an open-label, non-randomised phase 3 trial. Methods In this interim subset analysis of the TAUSSIG study, which was undertaken at 35 sites in 17 countries, we included patients aged 12 years or older with homozygous familial hypercholesterolaemia who were on stable LDL cholesterol-lowering therapy for at least 4 weeks; all patients received evolocumab 420 mg subcutaneously monthly, or if on apheresis every 2 weeks. Dosing could be increased to every 2 weeks after 12 weeks in patients not on apheresis. The primary outcome of the TAUSSIG study was treatment-emergent adverse events; secondary outcomes were the effects of evolocumab on LDL cholesterol and other lipids. We analysed patients on an intention-to-treat basis, and all statistical comparisons were done post hoc in this interim analysis. The TAUSSIG study is registered with ClinicalTrials.gov, number NCT01624142, and is ongoing. Findings 106 patients were included in this analysis, 34 receiving apheresis at study entry and 14 younger than 18 years. The first patient was enrolled on June 28, 2012, and the cutoff date for the analysis was Aug 13, 2015; mean follow-up was 1·7 years (SD 0·63). After 12 weeks, mean LDL cholesterol decreased from baseline by 20·6% (SD 24·4; mean absolute decrease 1·50 mmol/L [SD 1·92]); these reductions were maintained at week 48. 47 of 72 patients not on apheresis at study entry increased evolocumab dosing to every 2 weeks, with an additional mean reduction in LDL cholesterol of 8·3% (SD 13·0; mean absolute decrease 0·77 mmol/L [SD 1·38]; p=0·0001). In a post-hoc analysis, mean reductions in LDL cholesterol in patients on apheresis were significant at week 12 (p=0·0012) and week 48 (p=0·0032), and did not differ from reductions achieved in patients not on apheresis (p=0·38 at week 12 and p=0·09 at week 48). We noted a small reduction (median −7·7% [IQR −21·6 to 6·8]) in lipoprotein(a) at week 12 (p=0·0015), with some additional reduction at week 48 (–11·9% [−28·0 to 0·0]; p<0·0001). HDL cholesterol was increased by a mean of 7·6% (SD 18·1) at week 12 (p<0·0001) and 7·6% (SD 20·6) at week 48 (p=0·0007). Evolocumab was well tolerated; 82 (77%) patients reported treatment-emergent adverse events, which were mostly minor. The most common were nasopharyngitis (14 patients [13%]), influenza (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]). Serious adverse events occurred in 18 (17%) patients, with the most common being cardiovascular events (four patients [4%]). There were no deaths and four positively adjudicated cardiovascular events, one (3%) among patients on apheresis and three (4%) among patients who did not receive apheresis. Interpretation Our interim results suggest that evolocumab is an effective additional option to reduce LDL cholesterol in patients with homozygous familial hypercholesterolaemia, with or without apheresis. Funding Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿应助187798采纳,获得10
29秒前
40秒前
42秒前
44秒前
doubleshake发布了新的文献求助10
48秒前
h哈哈哈h应助doubleshake采纳,获得10
53秒前
不可靠的黏菌完成签到,获得积分10
58秒前
doubleshake完成签到,获得积分10
1分钟前
从容映易完成签到,获得积分10
1分钟前
充电宝应助科研通管家采纳,获得10
1分钟前
orixero应助科研通管家采纳,获得10
1分钟前
1分钟前
前前前世完成签到,获得积分10
1分钟前
戴哈哈发布了新的文献求助10
1分钟前
优雅的凝阳完成签到 ,获得积分10
1分钟前
无花果应助戴哈哈采纳,获得10
1分钟前
1分钟前
文静丹秋发布了新的文献求助10
1分钟前
戴哈哈完成签到,获得积分10
1分钟前
深情安青应助猪哥哥采纳,获得10
2分钟前
红橙黄绿蓝靛紫111完成签到,获得积分10
2分钟前
2分钟前
2分钟前
猪哥哥发布了新的文献求助10
2分钟前
2分钟前
道松先生发布了新的文献求助10
2分钟前
猪哥哥完成签到,获得积分20
2分钟前
科研通AI2S应助大胆绮采纳,获得60
2分钟前
CipherSage应助文静丹秋采纳,获得30
2分钟前
3分钟前
我是老大应助TT采纳,获得10
3分钟前
莽哥完成签到,获得积分10
3分钟前
3分钟前
鲤鱼慕晴完成签到,获得积分10
3分钟前
鲤鱼慕晴发布了新的文献求助10
3分钟前
3分钟前
隐形曼青应助科研通管家采纳,获得10
3分钟前
TT发布了新的文献求助10
3分钟前
3分钟前
187798发布了新的文献求助10
3分钟前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Востребованный временем 2500
Aspects of Babylonian celestial divination : the lunar eclipse tablets of enuma anu enlil 1500
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
Neuromuscular and Electrodiagnostic Medicine Board Review 700
Examining the relationship between working capital management and firm performance: a state-of-the-art literature review and visualisation analysis 500
Relativism, Conceptual Schemes, and Categorical Frameworks 500
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3445112
求助须知:如何正确求助?哪些是违规求助? 3041057
关于积分的说明 8983801
捐赠科研通 2729647
什么是DOI,文献DOI怎么找? 1497123
科研通“疑难数据库(出版商)”最低求助积分说明 692155
邀请新用户注册赠送积分活动 689674